Imugene Presents fresh onCARlytics data at SITC annual meeting
- Imugene (IMU) presents new data for its onCARlytics oncolytic virus at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, US
- The company presented two different sets — the first for a treatment with fellow biotech Celularity targeting tumours expressing a T-cell antigen known as CD19t
- The second set of data focused on onCARlytics in combination with an existing drug known as Blincyto to target solid tumours
- The company CEO and Managing Director Leslie Chong says the results further build the company’s confidence in its potential benefit to patients
- Shares in the company are up 4.05 per cent and trading at 19 cents at 12:13 pm AEDT
